140 related articles for article (PubMed ID: 34729537)
1. Management of Amyloid Cardiomyopathy in Resource-Constrained Settings: Challenges and Opportunities.
Singh S; Tandon R; Mohan B
JACC CardioOncol; 2021 Oct; 3(4):611-613. PubMed ID: 34729537
[No Abstract] [Full Text] [Related]
2. The diagnostic performance of cardiac magnetic resonance in detection of myocardial involvement in AL amyloidosis.
Fikrle M; Palecek T; Masek M; Kuchynka P; Straub J; Spicka I; Rysava R; Linhart A
Clin Physiol Funct Imaging; 2016 May; 36(3):218-24. PubMed ID: 25393773
[TBL] [Abstract][Full Text] [Related]
3. Amyloid fibril composition as a predictor of development of cardiomyopathy after liver transplantation for hereditary transthyretin amyloidosis.
Gustafsson S; Ihse E; Henein MY; Westermark P; Lindqvist P; Suhr OB
Transplantation; 2012 May; 93(10):1017-23. PubMed ID: 22395298
[TBL] [Abstract][Full Text] [Related]
4. Amyloid cardiomyopathy in systemic non-hereditary amyloidosis. Clinical, echocardiographic and electrocardiographic findings in 30 patients with AA and 24 patients with AL amyloidosis.
Hamer JP; Janssen S; van Rijswijk MH; Lie KI
Eur Heart J; 1992 May; 13(5):623-7. PubMed ID: 1618203
[TBL] [Abstract][Full Text] [Related]
5. Hypertrophic cardiomyopathy and symptomatic conduction system disease in cardiac amyloidosis.
Garg P; Gupta R; Hsi DH; Sheils LA; DiSalle MR; Woodlock TJ
South Med J; 2006 Dec; 99(12):1390-2. PubMed ID: 17233198
[TBL] [Abstract][Full Text] [Related]
6. Differentiation of cardiac amyloidosis and hypertrophic cardiomyopathy. A comparison of familial amyloidosis with polyneuropathy and hypertrophic cardiomyopathy by electrocardiography and echocardiography.
Eriksson P; Backman C; Eriksson A; Eriksson S; Karp K; Olofsson BO
Acta Med Scand; 1987; 221(1):39-46. PubMed ID: 3565084
[TBL] [Abstract][Full Text] [Related]
7. Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy.
Bennani Smires Y; Victor G; Ribes D; Berry M; Cognet T; Méjean S; Huart A; Roussel M; Petermann A; Roncalli J; Carrié D; Rousseau H; Berry I; Chauveau D; Galinier M; Lairez O
Int J Cardiovasc Imaging; 2016 Sep; 32(9):1403-1413. PubMed ID: 27240600
[TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin light-chain (AL) amyloidosis with myasthenic symptoms and echocardiographic features of dilated cardiomyopathy.
Yoshita M; Ishida C; Yanase D; Yamada M
Intern Med; 2006; 45(3):159-62. PubMed ID: 16508231
[TBL] [Abstract][Full Text] [Related]
9. Deeper Into Cardiac Amyloid: Potential for Improved Outcomes.
Pai RG; Varadarajan P
JACC Cardiovasc Imaging; 2017 Apr; 10(4):408-410. PubMed ID: 27639762
[No Abstract] [Full Text] [Related]
10. [Primary amyloidosis AL as a cause of restrictive cardiomyopathy].
Rückert Y; Hansen A; Dörffel WV; Eckert B; Scholze J
Z Kardiol; 1997 Oct; 86(10):812-7. PubMed ID: 9454448
[TBL] [Abstract][Full Text] [Related]
11. Left ventricular torsion by two-dimensional speckle tracking echocardiography in patient with a-type amyloid heart disease.
Karabay CY; Kocabay G
J Am Soc Echocardiogr; 2011 Jul; 24(7):818.e5-9. PubMed ID: 21074364
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the noninvasive strategies of cardiac amyloidosis.
Zhao L; Fang Q
Heart Fail Rev; 2016 Nov; 21(6):703-721. PubMed ID: 27554493
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of identifying amyloid and hypertrophic cardiomyopathy with the use of computerized quantitative texture analysis of clinical echocardiographic data.
Chandrasekaran K; Aylward PE; Fleagle SR; Burns TL; Seward JB; Tajik AJ; Collins SM; Skorton DJ
J Am Coll Cardiol; 1989 Mar; 13(4):832-40. PubMed ID: 2926037
[TBL] [Abstract][Full Text] [Related]
14. Outcome in patients treated with isolated liver transplantation for familial transthyretin amyloidosis to prevent cardiomyopathy.
Nelson LM; Penninga L; Villadsen GE; Mølgaard H; Eiskjaer H; Hillingsø JG; Rasmussen A
Clin Transplant; 2015 Dec; 29(12):1098-104. PubMed ID: 26361241
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy.
Benson MD; Dasgupta NR; Rissing SM; Smith J; Feigenbaum H
Amyloid; 2017 Dec; 24(4):219-225. PubMed ID: 28906150
[TBL] [Abstract][Full Text] [Related]
16. Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report.
Fujita T; Inomata T; Kaida T; Iida Y; Ikeda Y; Nabeta T; Ishii S; Maekawa E; Naruke T; Koitabashi T; Kitamura E; Sekijima Y; Ako J
Cardiology; 2017; 137(2):74-77. PubMed ID: 28152524
[TBL] [Abstract][Full Text] [Related]
17. Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management.
Hassan W; Al-Sergani H; Mourad W; Tabbaa R
Tex Heart Inst J; 2005; 32(2):178-84. PubMed ID: 16107109
[TBL] [Abstract][Full Text] [Related]
18. Improved Quantification of Cardiac Amyloid Burden in Systemic Light Chain Amyloidosis: Redefining Early Disease?
Cuddy SAM; Bravo PE; Falk RH; El-Sady S; Kijewski MF; Park MA; Ruberg FL; Sanchorawala V; Landau H; Yee AJ; Bianchi G; Di Carli MF; Cheng SC; Jerosch-Herold M; Kwong RY; Liao R; Dorbala S
JACC Cardiovasc Imaging; 2020 Jun; 13(6):1325-1336. PubMed ID: 32417333
[TBL] [Abstract][Full Text] [Related]
19. Cardiac amyloidosis mimicking hypertrophic cardiomyopathy.
Hemmingson LO; Eriksson P
Acta Med Scand; 1986; 219(4):421-3. PubMed ID: 3716885
[TBL] [Abstract][Full Text] [Related]
20. A special case of hypertrophic cardiomyopathy with a differential diagnosis of isolated cardiac amyloidosis or junctophilin type 2 associated cardiomyopathy.
De Bruijn S; Galloo X; De Keulenaer G; Prihadi EA; Brands C; Helbert M
Acta Clin Belg; 2021 Apr; 76(2):136-143. PubMed ID: 31478477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
